Latest Insider Transactions at Karuna Therapeutics, Inc. (KRTX)
This section provides a real-time view of insider transactions for Karuna Therapeutics, Inc. (KRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karuna Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karuna Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 02
2021
|
James Healy |
BUY
Open market or private purchase
|
Indirect |
636
+50.0%
|
$74,412
$117.8 P/Share
|
|
Jul 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$280,000
$112.66 P/Share
|
|
Jul 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Jun 24
2021
|
Heather Preston Director |
BUY
Other acquisition or disposition
|
Direct |
184
+2.73%
|
-
|
|
Jun 16
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,600
-8.69%
|
$332,800
$128.92 P/Share
|
|
Jun 16
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+7.71%
|
$23,400
$9.2 P/Share
|
|
Jun 14
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
900
-6.47%
|
$118,800
$132.52 P/Share
|
|
Jun 14
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+6.08%
|
$8,100
$9.2 P/Share
|
|
Jun 14
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
8,334
-15.48%
|
$1,091,754
$131.44 P/Share
|
|
Jun 14
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+13.41%
|
$75,006
$9.2 P/Share
|
|
Jun 11
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
8,333
-15.48%
|
$1,074,957
$129.33 P/Share
|
|
Jun 11
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+13.4%
|
$74,997
$9.2 P/Share
|
|
Jun 10
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
13,333
-22.66%
|
$1,639,959
$123.68 P/Share
|
|
Jun 10
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
13,333
+18.48%
|
$119,997
$9.2 P/Share
|
|
Jun 07
2021
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
4,000
-100.0%
|
$448,000
$112.93 P/Share
|
|
Jun 07
2021
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+50.0%
|
$336,000
$84.86 P/Share
|
|
Jun 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$277,500
$111.44 P/Share
|
|
Jun 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
May 12
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-1.52%
|
$24,000
$120.0 P/Share
|
|
May 12
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.49%
|
$1,800
$9.2 P/Share
|
|
May 10
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,000
-35.0%
|
$770,000
$110.07 P/Share
|
|
May 10
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+25.93%
|
$63,000
$9.2 P/Share
|
|
May 10
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-9.9%
|
$550,000
$110.43 P/Share
|
|
May 10
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.01%
|
$45,000
$9.2 P/Share
|
|
May 03
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$275,000
$110.61 P/Share
|
|
May 03
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Apr 13
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
1,264
+25.0%
|
-
|
|
Apr 13
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
150,000
-4.9%
|
-
|
|
Apr 13
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
1,756
+25.0%
|
-
|
|
Apr 13
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
150,000
-4.9%
|
-
|
|
Apr 12
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-9.9%
|
$570,000
$114.22 P/Share
|
|
Apr 12
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.01%
|
$45,000
$9.2 P/Share
|
|
Apr 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$300,000
$120.01 P/Share
|
|
Apr 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Mar 10
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-9.9%
|
$590,000
$118.48 P/Share
|
|
Mar 10
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.01%
|
$45,000
$9.2 P/Share
|
|
Mar 08
2021
|
Heather Preston Director |
BUY
Other acquisition or disposition
|
Direct |
572
+8.24%
|
-
|
|
Mar 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$312,500
$125.43 P/Share
|
|
Mar 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Feb 16
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-43.48%
|
$1,190,000
$119.57 P/Share
|
|
Feb 16
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.3%
|
$90,000
$9.2 P/Share
|
|
Feb 10
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-9.9%
|
$570,000
$114.06 P/Share
|
|
Feb 10
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.01%
|
$45,000
$9.2 P/Share
|
|
Feb 09
2021
|
Pure Tech Health LLC |
SELL
Open market or private sale
|
Direct |
1,000,000
-29.36%
|
$118,000,000
$118.0 P/Share
|
|
Feb 01
2021
|
Atul Pande |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$250,000
$100.0 P/Share
|
|
Feb 01
2021
|
Atul Pande |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Jan 11
2021
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-5.16%
|
$525,000
$105.11 P/Share
|
|
Jan 11
2021
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.87%
|
$40,000
$8.24 P/Share
|
|
Jan 08
2021
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,000
-38.1%
|
$832,000
$104.49 P/Share
|
|
Jan 08
2021
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+27.59%
|
$72,000
$9.2 P/Share
|